FDG-PET and beyond: Molecular breast cancer imaging

Journal of Clinical Oncology

Volumn 23, Issue 8, 2005, Pages 1664-1673

  Quon, Andrew ^a   Gambhir, Sanjiv S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE; LIPOCORTIN 5; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ANTIBODY ENGINEERING; APOPTOSIS; AXILLARY LYMPH NODE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; BREAST TUMOR; FEMALE; METABOLISM; METHODOLOGY; PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; STANDARD; TUMOR RECURRENCE;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 15544383053     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.024     Document Type: Review

References (59)

1. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:684-693, 2002
2. Pelosi E, Messa C, Sironi S, et al: Value of integrated PET/CT for lesion localization in cancer patients: A comparative study. Eur J Nucl Med Mol Imaging 31:932-939, 2004
3. Zangheri B, Messa C, Picchio M, et al: PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 31:S135-142, 2004 (suppl 1)
4. Avril N, Rose CA, Schelling M, et al: Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol 18:3495-3502, 2000
5. Wu D, Gambhir SS: Positron emission tomography in diagnosis and management of invasive breast cancer: Current status and future perspectives. Clin Breast Cancer 4:S55-S63, 2003 (suppl 1)
6. Schirrmeister H, Kuhn T, Guhlmann A, et al: Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28:351-358, 2001
7. Bernstein V, Jones A, Mankoff DA, et al: Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission tomography (FDG-PET) in medial hemisphere breast cancer. J Nucl Med 41:289, 2000 (suppl 5)
8. Palmedo H, Bender H, Grunwald F, et al: Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintiomammography in the detection of breast cancer. Eur J Nucl Med 24:1138-1145, 1997
9. Crippa F, Agresti R, Seregni E, et al: Prospective evaluation of fluorine-18 FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 39:4-8, 1998
10. Bos R, van Der Hoeven JJ, van Der Wall E, et al: Biologic correlates of [F18]fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379-387, 2002
11. Adler L, Crowe J, al-Kaisi N, et al: Evaluation of breast cancer masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187:743-750, 1993
12. Wahl RL, Zasadny K, Helvie M, et al: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11:2101-2111, 1993
13. Yutani K, Shiba E, Kusuoka H, et al: Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 24:274-280, 2000
14. Vranjesevic D, Schiepers C, Silverman DH, et al: Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med 44:1238-1242, 2003
15. Doshi NK, Shao Y, Silverman RW, et al: Design and evaluation of an LSO PET detector for breast cancer imaging. Med Phys 27:1535-1543, 2000
16. Adler L, Faulhaber P, Schnur K, et al: Axillary lymph node metastasis: Screening with [F-18] 2-deoxy-2-D-glucose-D-glucose PET. Radiology 203:323-327, 1997
17. Guller U, Nitzsche EU, Schirp U: Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D- glucose: Not yet! Breast Cancer Res Treat 71:171-173, 2002
18. Smith IC, Ogston K, Whitford P, et al: Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-D-glucose. Ann Surg 228:220-227, 1998
19. Greco M, Crippa F, Agresti R, et al: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography: Clinical evaluation and alternative management. J Natl Cancer Inst 93:630-635, 2001
20. van der Hoeven JJ, Hoekstra OS, Comans EF, et al: Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236:619-624, 2002
21. Lovrics P, Chen V, Coates G, et al: A prospective comparison of positron emission tomography scanning, sentinel lymph node biopsy and axillary dissection in staging patients with early stage breast cancer. Breast Cancer Res Treat 76:S129, 2002
22. Wahl RL, Siegel BA, Coleman R, et al: A prospective multicentre study of axillary nodal staging by positron emission tomography in breast cancer: A report of the staging breast cancer with PET study group. J Clin Oncol 22:277-285, 2004
23. Kelemen PR, Lowe V, Phillips N: Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 3:73-77, 2002
24. Guller U, Nitzsche E, Moch H, et al: Is positron emission tomography an accuate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients? J Natl Cancer Inst 95:1040-1043, 2003
25. Bellon JR, Livingston RB, Eubank WB, et al: Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 27:407-410, 2004
26. Eubank WB, Mankoff DA, Takasugi J, et al: 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19:3516-3523, 2001
27. Lonneux M, Borbath I, Berliere M, et al: The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3:45-49, 2000
28. Kao CH, Hsieh JF, Tsai SC, et al: Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 20:2189-2192, 2000
29. Lin WY, Tsai SC, Cheng KY, et al: Fluroine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer-Taiwanese experiences. Cancer Invest 20:725-729, 2002
30. Ohta M, Tokuda Y, Suzuki Y, et al: Whole body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with Tc-99m-MDP bone scintigraphy. Nucl Med Commun 22:875-879, 2001
31. Yang SN, Liang JA, Lin FJ, et al: Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128:325-328, 2002
32. Garcia JR, Simo M, Perez G, et al: 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients: Different affinity between lytic and sclerotic bone metastases. Eur J Nucl Med Mol Imaging 30:1714, 2003
33. Taira A, Herfkens RJ, Quon A, et al: Assessment of integrated FDG PET/CT imaging in the detection of bone metastases. Annual Meeting of the Radiology Society of North America, Chicago, IL, November 2004 (abstr)
34. Schelling M, Avril N, Nahrig J, et al: Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000
35. Bassa P, Kim EE, Inoue T, et al: Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37:931-938, 1996
36. Gennari A, Donati S, Salvadori B, et al: Role of 2-[18F]- fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 1:156-161, 2000
37. Hoh CK, Chap L, Glaspy JA, et al: Prognostic value of whole body FDG PET in breast cancer patients undergoing chemotherapy. J Nucl Med 39:254, 1998 (abstr; suppl)
38. Jansson T, Westlin JE, Ahlstrom H, et al: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer. A method for early therapy evaluation? J Clin Oncol 13:1470-1477, 1995
39. Mankoff DA, Dunnwald LK, Gralow JR, et al: Blood flow and metabolism in locally advanced breast cancer: Relationship to response to therapy. J Nucl Med 43:500-509, 2002
40. Schelling M, Avril N, Nahrig J, et al: Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000
41. Smith IC, Welch AE, Hutcheon AW, et al: Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000
42. Stafford SE, Gralow JR, Schubert EK, et al: Use of serial FDG PET to measure the response of bone-dominated breast cancer to therapy. Acad Radiol 9:913-921, 2002
43. Tiling R, Linke R, Untch M, et al: 18F-FDG PET and 99mTc-sestamibi scintiomammography for monitoring breast cancer response to neoadjuvant chemotherapy: A comparative study. Eur J Nucl Med 28:711-720, 2001
44. Dehdashti F, Flanagan FL, Mortimer JE, et al: Positron emission tomograpic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26:51-56, 1999
45. Mortimer JE, Dehdashti F, Siegel BA, et al: Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19:2797-2803, 2001
46. Reddel RR, Sutherland RL: Tamoxifen stimulation of human breast cancer cell proliferation in vitro: A possible model for tamoxifen. Eur J Cancer Clin Oncol 19:307-318, 1983
47. Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, et al: Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2:229-234, 2001
48. Suarez M, Perez-Castejon MJ, Jimenez A, et al: Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46:113-121, 2002
49. Fueger B, Quon A, Auerbach M, et al: Comparison of FDG PET, PET/CT, and multimodality fusion software in breast cancer. J Nucl Med 45:86, 2004 (abstr 246; suppl)
50. Ciernik IF, Dizendorf E, Baumert BG, et al: Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 57:853-863, 2003
51. Giraud P, Grahek D, Montravers F, et al: (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 49:1249-1257, 2001
52. Smyczek-Gargya B, Fersis N, Dittmann H, et al: PET with [18F]fluorothymidine for imaging of primary breast cancer: A pilot study. Eur J Nucl Med Mol Imaging 31:720-724, 2004
53. Pio BS, Park CK, Silverman DH: PET with fluoro-L-thymididne allows early prediction of breast cancer response to chemotherapy. J Nucl Med 44:76P-77P, 2003 (abstr; suppl)
54. Spence AM, Mankoff DA, Muzi M: Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 13:717-739, 2003
55. McGuire AH, Dehdashti F, Siegel BA, et al: Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32:1526-1531, 1991
56. Mankoff DA, Peterson LM, Stekhova S, et al: Uptake of [F-18]-Fluoroestradiol (FES) predicts response of recurrent or metastatic breast cancer to hormonal therapy. J Nucl Med 44:126, 2003 (abstr; suppl)
57. Kortt AA, Dolezal O, Power BE, et al: Dimeric and trimeric antibodies: High avidity scFvs for cancer targeting. Biomol Eng 18:95-108, 2001
58. Wu AM, Yazaki PJ: Designer genes: Recombinant antibody fragments for biological imaging. Q J Nucl Med 44:268-283, 2000
59. 2, against Her2/neu for imaging of breast cancer. Era of Hope 2002 Department of Defense Breast Cancer Research Program Meeting, Orlando, FL, 2002